Thailand, the first country in Asia to decriminalize cannabis in 2022, is now introducing stricter regulations that limit its sale and use. While the cannabis boom fueled tourism, investment, and agricultural growth, recent changes signal a new phase of regulatory oversight.
šæ New Policy: Prescription Now Required for Cannabis Sales
Thailandās Ministry of Public Health has officially announced a regulation requiring a valid medical prescription for purchasing cannabis. This move seeks to address growing concerns about under-regulation, youth access, and addiction. The new orderāsigned by Health Minister Somsak Thepsutināalso proposes reclassifying cannabis buds as a controlled herb.
This regulation will come into effect once published in the Royal Gazette.
š§Ŗ Why the Shift?
Government agencies, including the Office of the Narcotics Control Board (ONCB), have cited a spike in cannabis misuse, particularly among youth. A 2024 ONCB study reported a significant rise in addiction cases post-decriminalization. Additionally, recent months have seen a surge in cannabis smuggling by tourists, prompting security concerns.
šļø Political Background
The ruling Pheu Thai Party, which previously supported re-criminalizing cannabis, has renewed its stance following public pressure. However, resistance from its former coalition partnerāthe Bhumjaithai Party, a key force behind legalizationāhas led to political friction. Bhumjaithai recently withdrew from the coalition government.
š£ Public Reaction
The move has triggered criticism from cannabis advocacy groups. They argue that the changes are politically motivated and threaten the progress made in building a sustainable cannabis economy. Protests are already being planned at the Ministry of Public Health next month.
š What This Means for Investors and Bicaro Group
Despite these shifts, Bicaro Group remains confident in the long-term potential of Thailandās cannabis industry. Regulatory clarity often strengthens market trust and ensures high standards for cultivation and distributionāsomething Bicaro has always prioritized.
With our GACP- and GMP-compliant facilities, dual indoor and outdoor grow models, and a focus on medical cannabis and wellness tourism, we are well-positioned to operate within new regulations and continue to grow responsibly.
ā Key Takeaways for Investors
- Cannabis sales now require a prescription under Thailand’s updated policy.
- Cannabis buds to be reclassified as a controlled herb.
- The shift may limit unregulated use but reinforces opportunities for licensed, high-standard operators like Bicaro Group.
- Bicaroās compliance-first approach and sustainable model offer investors confidence and security in a changing landscape.
š Learn more: www.bicarogroup.com
š© Contact us: calvin@bicarogroup.com
š± WhatsApp: +66 65 242 5513
š· Instagram: @bicaroholding
š Facebook: BicaroHolding